Dr. Philippe Backeljauw of Cincinnati Children's Hospital says that the drug called Increlex will treat children whose growth failure is related to unusually low levels of a hormone called IGF-1.
Tercica Inc., the manufacturer of Increlex, says that almost 6,000 children in the U.S. are suffering from the condition.
According to The Associated Press
Although the side effects include low blood sugar and skin lumps, the company claims that no patients withdrew from the trial because of them.
Tercica launched U.S. operations in 2002 after winning exclusive rights to manufacture the growth drug from the biotech company Genentech.
